checkAd

     331  0 Kommentare Sernova to Present at Global Partnership Family Office - HealthCare & Biotechnology TSX Showcase - Seite 2

    - Demonstrated preclinical proof-of-concept showing improvement in blood clotting with human cells using an ex vivo gene therapy approach for hemophilia A

    - Demonstrated preclinical proof-of-concept with transplanted human thyroid tissue for management of hypothyroid disease.

    - Multiple research collaborations in place with pharmaceutical industry leaders.

    About Global Partnership Family Office (GPFO) and International Deal Gateway (IDG)

    International Deal Gateway's Family Office Events provide a unique opportunity for public and private companies to gain access to an exclusive group of 2,400 ultra-high net worth investors and family offices throughout Europe through their long-standing relationship with GPFO. Together, IDG and GPFO look forward to hosting the TSX sponsored Healthcare & Biotechnology Showcase, a collection of extraordinary select companies working to improve health outcomes with a focus on longevity, healthcare, biotechnology and data.

    GPFO has been the 'eyes and ears' of the global family office community for over a decade. Providing salient, timely and impartial briefings, insights and opportunities to its membership.

    Dr. Michael J. Oliver, GPFO founder, "We have been delighted to grow our partnership with IDG over the years, providing our community with insights from the brightest minds and leaders from across the Atlantic, offering a bridge for many of our network who have deep familial and business ties to Canada and the US."

    About Sernova

    Sernova is developing regenerative medicine therapeutic technologies using its Cell Pouch medical device, therapeutic cells (i.e., human donor cells, corrected human cells, stem cell-derived cells and tissues) and immune protection technologies to improve the treatment and quality of life of people living with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com.

    Seite 2 von 3


    Diskutieren Sie über die enthaltenen Werte


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    Sernova to Present at Global Partnership Family Office - HealthCare & Biotechnology TSX Showcase - Seite 2 DGAP-Media / 17.05.2021 / 15:55 LONDON, ON - May 17, 2021 -- Sernova Corp. (TSX-V:SVA)(FSE/XETRA:PSH)(OTCQB:SEOVF), a leading clinical-stage company focused on regenerative medicine therapeutics, today announced that Dr. Philip Toleikis, President …

    Schreibe Deinen Kommentar

    Disclaimer